Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus

NCT00690066 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.

NCT NCT00690066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00690066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus
Lead sponsor
Mesoblast, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 11, 2008
Completion date
December 19, 2011
Enrollment
63 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, insulin-dependent, juvenile diabetes, type 1 diabetes, type 1 diabetes mellitus